Articles from Diorasis Therapeutics
Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Dimitri Azar, MD, MBA, AM (hon.), DHL (hon.), to its Board of Directors.
By Diorasis Therapeutics · Via Business Wire · October 17, 2025